ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH THE JUVENILE IDIOPATHIC ARTHRITIS TREATED BY THE ETANERCEPT

Abstract

Aim : To assess the influence of the genetically engineered biologic drug etanercept on the quality of life of patients with juvenile idiopathic arthritis (JIA). Patients and methods : The research included 85 children with poly-and oligoarticular variant of the JIA at the age of 5 (2; 17) years. The assessment of the quality of life of patients was carried out by means of the parental version of a special questionnaire CHAQ (Childhood Health Assessment Questionnaire), Health Utilities Index Mark 3 (HUI3) questionnaire. The doctor and parents of the patient also assessed the global activity of the illness by the 100-mm visual analog scale (VAS) before the etanercept prescription and in 1, 6 and 12 months. All patients before the etanercept prescription received immunodepressants. Results : Fast dynamics of the increase of an average point of the quality of life (the response in 1 month after the therapy beginning) was noted by the attributes of a questionnaire of HUI3 «emotions» — from 0.82 (± 0.18) to 0.90 (± 0.13), p =0.001, «cognitive abilities» — from 0.85 (± 0.17) to 0.91 (± 0.18), p =0.006, and «pain» — from 0.78 (± 0.23) to 0.91 (± 0.1), p < 0.001. In 12 months of the treatment the average point of the quality of life raised also by such attributes as «locomotivity» — from 0.85 (± 0.3) to 0.99 (± 0.06), p < 0.0001, and «fine motor skills» — from 0.9 (± 0.19) to 0.98 (± 0.05), p < 0.001. Conclusion: Treatment with the etanercept provided the improvement of the quality of life of children with the JIA and their families, improvement of physical activity and emotional state of patients. Key words : children, juvenile idiopathic arthritis, etanercept, quality of life, Health Utilities Index Mark 3.